CGB-600 | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

9,546 results for “CGB-600”

Trials

View all 6361 →

A Proof of Concept, Phase 1 Study of CGB-600 for the Topical Treatment of Non-Segmented Facial Vitiligo

36 participants · First posted Jan 22, 2026

CGB-400 for the Reduction of Facial Redness

25 participants · First posted Aug 11, 2020

CGB-400 for the Reduction of Facial Redness and Bumps and Blemishes

27 participants · First posted Aug 11, 2020

Drugs

View all 1901 →

CGB-400

CGB-1001

Organizations

View all 13 →

FGK Representative Service GmbH

Germany

Hamlet BioPharma AB

Sweden

Mediprint Ophthalmics, Inc.

United States

News

View all 1271 →

CAGE Bio Initiates Phase 2 Trial of First-in-Class DNA Aptamer Therapy CGB-600 for Vitiligo Treatment

Advancements in CGB-500 for Atopic Dermatitis Treatment

CAGE Bio Initiates Phase 2b Trial of Topical JAK Inhibitor CGB-500 for Atopic Dermatitis

Page 1 of 955